AI may be more accurate vs. traditional methods at classifying patients into prostate cancer risk groups

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

For localized prostate cancer, multimodal artificial intelligence models have revealed a more accurate way to assess prostate cancer risk.  By combining advanced artificial intelligence with digital pathology images and clinical data, researchers developed a way to approach risk classification that outperforms traditional methods. These findings were published in JCO Precision Oncology. The research found that...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising. 
The National Institute for Health Care Management Foundation is now accepting letters of inquiry for the 2025-2026 funding cycle of NIHCM Foundation’s Research Grant program. We will be awarding a total of $500,000 in grants to support innovative, independent, investigator-initiated research that has the potential to inform managed care organizations, policymakers, and related stakeholders to improve the affordability and quality of U.S. health care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login